PET staging of amyloidosis using striatum

Bernard J. Hanseeuw; Rebecca A. Betensky; Elizabeth C. Mormino; Aaron P. Schultz; Jorge Sepulcre; John A. Becker; Heidi I. L. Jacobs; Rachel F. Buckley; Molly R. LaPoint; Patrizia Vannini; Nancy J. Donovan; Jasmeer P. Chhatwal; Gad A. Marshall; Kathryn Papp; Rebecca E. Amariglio; Dorene M. Rentz; Reisa A. Sperling; Keith A. Johnson; Alzheimers Dis Neuroimaging Initia; Harvard Aging Brain Study

doi:10.1016/j.jalz.2018.04.011

PET staging of amyloidosis using striatum

Bernard J. Hanseeuw^*, Rebecca A. Betensky, Elizabeth C. Mormino, Aaron P. Schultz, Jorge Sepulcre, John A. Becker, Heidi I. L. Jacobs, Rachel F. Buckley, Molly R. LaPoint, Patrizia Vannini, Nancy J. Donovan, Jasmeer P. Chhatwal, Gad A. Marshall, Kathryn Papp, Rebecca E. Amariglio, Dorene M. Rentz, Reisa A. Sperling, Keith A. Johnson, Alzheimers Dis Neuroimaging Initia; Harvard Aging Brain Study

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Introduction: Amyloid positron emission tomography (PET) data are commonly expressed as binary measures of cortical deposition. However, not all individuals with high cortical amyloid will experience rapid cognitive decline. Motivated by postmortem data, we evaluated a three-stage PET classification: low cortical; high cortical, low striatal; and high cortical, high striatal amyloid; hypothesizing this model could better reflect Alzheimer's dementia progression than a model based only on cortical measures. Methods: We classified PET data from 1433 participants (646 normal, 574 mild cognitive impairment, and 213 AD), explored the successive involvement of cortex and striatum using 3-year follow-up PET data, and evaluated the associations between PET stages, hippocampal volumes, and cognition. Results: Follow-up data indicated that PET detects amyloid first in cortex and then in striatum. Our three-category staging including striatum better predicted hippocampal volumes and subsequent cognition than a three-category staging including only cortical amyloid. Discussion: PET can evaluate amyloid expansion from cortex to subcortex. Using striatal signal as a marker of advanced amyloidosis may increase predictive power in Alzheimer's dementia research. (C) 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association.

Original language	English
Pages (from-to)	1281-1292
Number of pages	12
Journal	Alzheimer's & Dementia
Volume	14
Issue number	10
DOIs	https://doi.org/10.1016/j.jalz.2018.04.011
Publication status	Published - 1 Oct 2018

Keywords

Amyloid PET imaging
Structural MRI
Striatum
Cortex
Cognitive aging
MCI
Alzheimer's disease
Classification
Staging
MILD COGNITIVE IMPAIRMENT
PITTSBURGH COMPOUND B
PRECLINICAL ALZHEIMER-DISEASE
NEUROIMAGING INITIATIVE ADNI
A-BETA
PROSPECTIVE COHORT
COMPOSITE SCORE
HUMAN BRAIN
DEPOSITION
DECLINE

Access to Document

10.1016/j.jalz.2018.04.011Licence: CC BY

https://doi.org/10.1016/j.jalz.2018.04.011

Cite this

Hanseeuw, B. J., Betensky, R. A., Mormino, E. C., Schultz, A. P., Sepulcre, J., Becker, J. A., Jacobs, H. I. L., Buckley, R. F., LaPoint, M. R., Vannini, P., Donovan, N. J., Chhatwal, J. P., Marshall, G. A., Papp, K., Amariglio, R. E., Rentz, D. M., Sperling, R. A., Johnson, K. A., & Alzheimers Dis Neuroimaging Initia; Harvard Aging Brain Study (2018). PET staging of amyloidosis using striatum. Alzheimer's & Dementia, 14(10), 1281-1292. https://doi.org/10.1016/j.jalz.2018.04.011

@article{c7532f818f5f4775b0a8b84629d903e4,

title = "PET staging of amyloidosis using striatum",

abstract = "Introduction: Amyloid positron emission tomography (PET) data are commonly expressed as binary measures of cortical deposition. However, not all individuals with high cortical amyloid will experience rapid cognitive decline. Motivated by postmortem data, we evaluated a three-stage PET classification: low cortical; high cortical, low striatal; and high cortical, high striatal amyloid; hypothesizing this model could better reflect Alzheimer's dementia progression than a model based only on cortical measures. Methods: We classified PET data from 1433 participants (646 normal, 574 mild cognitive impairment, and 213 AD), explored the successive involvement of cortex and striatum using 3-year follow-up PET data, and evaluated the associations between PET stages, hippocampal volumes, and cognition. Results: Follow-up data indicated that PET detects amyloid first in cortex and then in striatum. Our three-category staging including striatum better predicted hippocampal volumes and subsequent cognition than a three-category staging including only cortical amyloid. Discussion: PET can evaluate amyloid expansion from cortex to subcortex. Using striatal signal as a marker of advanced amyloidosis may increase predictive power in Alzheimer's dementia research. (C) 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association.",

keywords = "Amyloid PET imaging, Structural MRI, Striatum, Cortex, Cognitive aging, MCI, Alzheimer's disease, Classification, Staging, MILD COGNITIVE IMPAIRMENT, PITTSBURGH COMPOUND B, PRECLINICAL ALZHEIMER-DISEASE, NEUROIMAGING INITIATIVE ADNI, A-BETA, PROSPECTIVE COHORT, COMPOSITE SCORE, HUMAN BRAIN, DEPOSITION, DECLINE",

author = "Hanseeuw, {Bernard J.} and Betensky, {Rebecca A.} and Mormino, {Elizabeth C.} and Schultz, {Aaron P.} and Jorge Sepulcre and Becker, {John A.} and Jacobs, {Heidi I. L.} and Buckley, {Rachel F.} and LaPoint, {Molly R.} and Patrizia Vannini and Donovan, {Nancy J.} and Chhatwal, {Jasmeer P.} and Marshall, {Gad A.} and Kathryn Papp and Amariglio, {Rebecca E.} and Rentz, {Dorene M.} and Sperling, {Reisa A.} and Johnson, {Keith A.} and {Alzheimers Dis Neuroimaging Initia; Harvard Aging Brain Study}",

year = "2018",

month = oct,

day = "1",

doi = "10.1016/j.jalz.2018.04.011",

language = "English",

volume = "14",

pages = "1281--1292",

journal = "Alzheimer's & Dementia",

issn = "1552-5260",

publisher = "Elsevier Science",

number = "10",

}

Hanseeuw, BJ, Betensky, RA, Mormino, EC, Schultz, AP, Sepulcre, J, Becker, JA, Jacobs, HIL, Buckley, RF, LaPoint, MR, Vannini, P, Donovan, NJ, Chhatwal, JP, Marshall, GA, Papp, K, Amariglio, RE, Rentz, DM, Sperling, RA, Johnson, KA & Alzheimers Dis Neuroimaging Initia; Harvard Aging Brain Study 2018, 'PET staging of amyloidosis using striatum', Alzheimer's & Dementia, vol. 14, no. 10, pp. 1281-1292. https://doi.org/10.1016/j.jalz.2018.04.011

TY - JOUR

T1 - PET staging of amyloidosis using striatum

AU - Hanseeuw, Bernard J.

AU - Betensky, Rebecca A.

AU - Mormino, Elizabeth C.

AU - Schultz, Aaron P.

AU - Sepulcre, Jorge

AU - Becker, John A.

AU - Jacobs, Heidi I. L.

AU - Buckley, Rachel F.

AU - LaPoint, Molly R.

AU - Vannini, Patrizia

AU - Donovan, Nancy J.

AU - Chhatwal, Jasmeer P.

AU - Marshall, Gad A.

AU - Papp, Kathryn

AU - Amariglio, Rebecca E.

AU - Rentz, Dorene M.

AU - Sperling, Reisa A.

AU - Johnson, Keith A.

AU - Alzheimers Dis Neuroimaging Initia; Harvard Aging Brain Study

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Introduction: Amyloid positron emission tomography (PET) data are commonly expressed as binary measures of cortical deposition. However, not all individuals with high cortical amyloid will experience rapid cognitive decline. Motivated by postmortem data, we evaluated a three-stage PET classification: low cortical; high cortical, low striatal; and high cortical, high striatal amyloid; hypothesizing this model could better reflect Alzheimer's dementia progression than a model based only on cortical measures. Methods: We classified PET data from 1433 participants (646 normal, 574 mild cognitive impairment, and 213 AD), explored the successive involvement of cortex and striatum using 3-year follow-up PET data, and evaluated the associations between PET stages, hippocampal volumes, and cognition. Results: Follow-up data indicated that PET detects amyloid first in cortex and then in striatum. Our three-category staging including striatum better predicted hippocampal volumes and subsequent cognition than a three-category staging including only cortical amyloid. Discussion: PET can evaluate amyloid expansion from cortex to subcortex. Using striatal signal as a marker of advanced amyloidosis may increase predictive power in Alzheimer's dementia research. (C) 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association.

AB - Introduction: Amyloid positron emission tomography (PET) data are commonly expressed as binary measures of cortical deposition. However, not all individuals with high cortical amyloid will experience rapid cognitive decline. Motivated by postmortem data, we evaluated a three-stage PET classification: low cortical; high cortical, low striatal; and high cortical, high striatal amyloid; hypothesizing this model could better reflect Alzheimer's dementia progression than a model based only on cortical measures. Methods: We classified PET data from 1433 participants (646 normal, 574 mild cognitive impairment, and 213 AD), explored the successive involvement of cortex and striatum using 3-year follow-up PET data, and evaluated the associations between PET stages, hippocampal volumes, and cognition. Results: Follow-up data indicated that PET detects amyloid first in cortex and then in striatum. Our three-category staging including striatum better predicted hippocampal volumes and subsequent cognition than a three-category staging including only cortical amyloid. Discussion: PET can evaluate amyloid expansion from cortex to subcortex. Using striatal signal as a marker of advanced amyloidosis may increase predictive power in Alzheimer's dementia research. (C) 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association.

KW - Amyloid PET imaging

KW - Structural MRI

KW - Striatum

KW - Cortex

KW - Cognitive aging

KW - MCI

KW - Alzheimer's disease

KW - Classification

KW - Staging

KW - MILD COGNITIVE IMPAIRMENT

KW - PITTSBURGH COMPOUND B

KW - PRECLINICAL ALZHEIMER-DISEASE

KW - NEUROIMAGING INITIATIVE ADNI

KW - A-BETA

KW - PROSPECTIVE COHORT

KW - COMPOSITE SCORE

KW - HUMAN BRAIN

KW - DEPOSITION

KW - DECLINE

U2 - 10.1016/j.jalz.2018.04.011

DO - 10.1016/j.jalz.2018.04.011

M3 - Article

C2 - 29792874

SN - 1552-5260

VL - 14

SP - 1281

EP - 1292

JO - Alzheimer's & Dementia

JF - Alzheimer's & Dementia

IS - 10

ER -